Chronic Generalized Periodontitis Clinical Trial
Official title:
Moxifloxacin In Situ Gel as an Adjunct in the Treatment of Periodontal Pocket: A Randomized Clinical Trial.
In this Randomized clinical trial locally delivered moxifloxacin in situ gel was evaluated as an adjunct to scaling and root planing for efficacy in the treatment of chronic periodontitis and for short-term effects on the periodontal microflora.
Moxifloxacin exerts excellent antibacterial activity against a wide range of putative
periodontal pathogens, including Porphyromonas gingivalis, Tannerella forsythia, Prevotella
species, Fusobacterium nucleatum, Actinomyces species, Peptostreptococcus species,
Campylobacter rectus, and Actinobacillus actinomycetemcomitans. Moxifloxacin penetrates well
into soft tissues and is effective against intracellular periodontal pathogens when used in
the treatment of periodontitis as an adjunct to scaling and root planning (SRP). Systemic
administration of moxifloxacin has provided superior outcomes compared with SRP in
conjunction with systemic administration of doxycycline, or SRP alone. We hypothesized
similar benefits with local drug delivery of Moxifloxacin in the treatment of chronic
periodontitis. To the best of our knowledge, there is no published literature on in situ gel
using moxifloxacin employing gellan gum as the vehicle, for direct placement in the
periodontal pocket for the treatment of chronic periodontitis.
Among various drug delivery systems for treating periodontitis, gel formulations have some
advantages. Despite a relatively faster release of the drug, gels can be more easily prepared
and administered. Moreover, they possess a higher bio compatibility and bio adhesivity, by
allowing adhesion to the mucosa in the dental pocket and by decreasing the risk of dilution
of the material by saliva.
Keeping the above facts in mind, the goals of this study were to (1) evaluate in situ gel as
a vehicle in a local drug delivery system, (2) evaluate the efficacy of moxifloxacin for
local drug delivery, (3) evaluate the efficacy of gellan gum for in situ gelation of
moxifloxacin, and (4) evaluate and compare the clinical and microbiological parameters of
moxifloxacin with those of the gold standard, chlorhexidine di gluconate.
;